Reshma Kewalramani - Dec 15, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Dec 15, 2023
Transactions value $
-$3,858,352
Form type
4
Date filed
12/19/2023, 04:15 PM
Previous filing
Dec 15, 2023
Next filing
Feb 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $476K +3.06K +2.81% $155.57 112K Dec 15, 2023 Direct
transaction VRTX Common Stock Options Exercise $2.64M +14.1K +12.59% $187.53 126K Dec 15, 2023 Direct
transaction VRTX Common Stock Sale -$6.97M -17.1K -13.62% $407.00 109K Dec 15, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -3.06K -100% $0.00* 0 Dec 15, 2023 Common Stock 3.06K $155.57 Direct F2
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -14.1K -89.99% $0.00 1.57K Dec 15, 2023 Common Stock 14.1K $187.53 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023.
F2 Fully vested.